

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Robert M. LORENCE et al

Serial No. 08/260,536

Filed: June 16, 1994



Atty. Ref.: 2370-11

TC/A.U.: 1648

Examiner: Le, Emily M.

For: METHODS FOR TREATING AND DETECTING CANCER USING VIRUSES

* * * * *

July 5, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449.

This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Pursuant to Rule 37 C.F.R. §1.97(c), a fee of \$180.00 as specified in Rule 17(p) is attached. If there is any shortage in the fee, please charge the deposit account of Nixon & Vanderhye, Account No. 14-1140.

Respectfully submitted,


NIXON & VANDERHYE P.C.

07/06/2005 SDENBOB1 00000082 08260536

03 FC:1806

180.00 0P

By:


Leonard C. Mitchard
Reg. No. 29,009

LCM:lfm

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT

Robert M. LORENCE et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

June 16, 1994

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Clercq, E.D., et al; "Current Concepts of Interferon and Interferon Induction"; <i>Division of Infectious Diseases, Dept. of Medicine, Stanford University School of Medicine, Stanford, California</i> ; pp. 17-46 (1970).
	Hilleman, M.R.; "Interferon Induction and Utilization"; <i>J. Cell Physiol.</i> ; Vol. 71 pp. 43-60 (1968).
	Eaton, M.D., et al; "Contribution of Antiviral Immunity to Oncolysis by Newcastle Disease Virus in a Murine Lymphoma"; <i>Journal of the National Cancer Institute</i> ; Vol. 39, No. 1-6 pp. 1089-1097 (1967).
	Dalglish, A.G., et al; "The Development of Therapeutic Vaccines for the Management of Malignant Melanoma"; <i>Cancer Surveys</i> , Vol. 26; pp. 289-319 (1996).
	Japanese Patent Office; Public Patent Disclosure Bulletin No. S51-73117; Bulletin Date June 24, 1976; Patent Application No. S49-147261; Patent Application Date; December 19, 1974, (6 pgs).
	Nature New Biology; Vol. 245, No. 147, October 24, 1973, "Role of Interferon in the Anti-Melanoma Effects of Poly (I), Poly (C) and Newcastle Disease Virus; pp 229-230.
	Baars, A., et al; "Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients"; <i>Annals of Oncology</i> ; Vol. 11, pp. 965-970 (2000).
	Schirmacher, V.; "In situ analysis of tumor-specific CTL effector and memory responses elicited by tumor vaccination"; <i>International Journal of Oncology</i> ; Vol. 15; pp. 27-227 (1999).
	Vile, R.G.; "Vironcology-not yet, but soon?"; <i>Nature Biotechnology</i> , Nature Publishing Group; Vol. 19 pp. 1020-1022, (2001).
	Yotnda, P., et al; "Targeted delivery of adenoviral vectors by cytotoxic T cells"; <i>Blood</i> ; Vol. 104, No. 8, pp 2272-2280 (2004).
	Harrington, K., et al; "Cells as Vehicles for Cancer Gene Therapy: The Missing Link Between Targeted Vectors and Systemic Delivery"; <i>Human Gene Therapy</i> ; Vol. 13; pp. 1263-1280 (2002).
	Crystal, R.G., et al; "Analysis of Risk Factors for Local Delivery of Low- and Intermediate-Dose Adenovirus Gene Transfer Vectors to Individuals with a Spectrum of Comorbid Conditions"; <i>Human Gene Therapy</i> ; Vol. 13; pp. 65-100 (2002).
	Chen, Y., et al; "Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human Therapy"; <i>Human Gene Therapy</i> ; Vol. 11; pp. 1553-1567 (2000).
	Jia, W., et al; "Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting"; <i>Current Gene Therapy</i> ; Vol. 5, pp. 133-142 (2005).
	Morrissey, R.E., et al; "Rodent Nonclinical Safety Evaluation Studies of SCH 58500, an Adenoviral Vector for the p53 Gene"; <i>Toxicological Sciences</i> ; Vol. 65, pp. 266-275 (2002).
	Plager, C., et al; "Adjuvant Immunotherapy of M.D. Anderson Hospital (MDAH Stage III-B Malignant Melanoma with Newcastle Disease Virus Oncolysate"; <i>Proceedings of American Society of Clinical Oncology</i> ; Vol. 9 p 281; #1091 (March 1990)
	Leibrich, W., et al; "In vitro and Clinical Characterisation of a Newcastle Disease Virus-modified Autologous Tumour Cell Vaccine for Treatment of Colorectal Cancer Patients"; <i>Eur J. Cancer</i> ; Vol. 27, No. 6, pp (703-710 (1991).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT

Robert M. LORENCE et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

June 16, 1994

1648

	Mallmann, P.; "Autologous Tumor-Cell Vaccination and Lymphokine-Activated Tumor-Infiltrating Lymphocytes (LAK-TIL); <i>Hybridoma</i> ; Vol. 12, No. 5, pp 559-566 (1993).
	Murray, D.R., et al; "Viral Oncolysate in the Management of Malignant Melanoma II. Clinical Studies"; <i>Cancer</i> ; Vol. 46, No. 2; pp680-686 (1977).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.